Clinical trials: Relapsed Cancer
T-cell Lymphoma
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma.
- Trial name
- GI-hNeoT-01 (NCT06224049)
- Testing
- hNeo-T, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- BGI, China
Multiple Myeloma
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM.
- Trial name
- CC-220 (NCT05560399)
- Testing
- Iberdomide, Elotuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsed and Refractory, Lymphoid Hematological Malignancies
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.
- Trial name
- NCT04283006
- Testing
- CD20/CD22 dual Targeted CAR T-cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- He Huang
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or…
- Trial name
- NCT06367114
- Testing
- ssCART-19, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some…
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
- Trial name
- NCT04189952
- Testing
- Acalabrutinib, Rituximab, Ifosfamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
Up Until now, there is not well acepted treatment for relapsed/refractory (rr) acute myeloid luekemia (AML), which has low complete response and poor survival.
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia, Salvage Treatment, HVA Regimen
- Trial name
- NCT04424147
- Testing
- HVA Regimens as Salvage Treatment
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lymphoma
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an international, multicenter study (with…
- Trial name
- NCT03070964
- Testing
- plitidepsin
- Where
- 17 sites in United States, Czechia and 2 more
- Volunteers
- 14 people
- Sponsor
- PharmaMar
Lymphoma
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma.
- Trial name
- NCT04464798
- Testing
- CC-220, Rituximab, Obinutuzumab
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- Celgene
Refractory Neuroblastoma, Soft Tissue Cancer
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft…
- Trial name
- NICE (NCT06438614)
- Testing
- HITS, Naxitamab + GM-CSF cycles, NICE
- Where
- Spain
- Volunteers
- 47 people
- Sponsor
- Fundació Sant Joan de Déu
Relapsed/Refractory B-Cell Lymphoma
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL).
- Trial name
- NCT05950334
- Testing
- FT522, Rituximab, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Acute Myelogenous Leukemia
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid…
- Trial name
- NCT03971799
- Testing
- CD33CART autologous, CD33CART allogeneic
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Hodgkin's Lymphoma
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase II trial studies how well umbralisib and pembrolizumab work in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03776864
- Testing
- Pembrolizumab, Umbralisib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Breast Cancer Stage IV
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was…
- Trial name
- SAFIR 03 (NCT05625087)
- Testing
- Alpelisib, Ribociclib
- Where
- 44 sites in France
- Volunteers
- 4 people
- Sponsor
- UNICANCER
Solid Tumor, Adult
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).
- Trial name
- NCT05309187
- Testing
- IO-202, IO-202 + pembrolizumab combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types
- Where
- 10 sites in United States
- Volunteers
- 22 people
- Sponsor
- Immune-Onc Therapeutics
Leukemia, Neutropenia
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002693
- Testing
- filgrastim, carboplatin, topotecan hydrochloride
- Where
- United States
- Sponsor
- Mayo Clinic
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Myeloid Malignancy, Acute Myeloid Leukemia
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age…
- Conditions
- Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06594445
- Testing
- GTB-360
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Extranodal NK/T-cell Lymphoma, Nasal Type
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
- Trial name
- NCT04405375
- Testing
- gemcitabin, Pegaspargase, Etoposide
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Beijing Tongren Hospital
Hairy Cell Leukemia
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Background: Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people.
- Trial name
- NCT04324112
- Testing
- binimetinib, Encorafenib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)